financetom
Business
financetom
/
Business
/
Ernst & Young calls off plan to split audit, consulting units
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ernst & Young calls off plan to split audit, consulting units
Apr 11, 2023 11:31 PM

Accounting firm Ernst & Young (EY) has called off a plan to break up its audit and consulting units, slamming the brakes on a proposed overhaul of its businesses that was meant to address regulatory concerns over potential conflicts of interest.

Share Market Live

NSE

The company, which is one of the Big Four accounting giants, announced its plans for a split in September after regulators voiced concerns that the audit arm would not do its job fairly for its client if it also employed EY as a consultant.

But the plan, code-named "Project Everest", faced resistance from some of EY's partners. The company said its US Executive Committee decided not to move forward with the split.

Had the split been ratified, it would have been the biggest overhaul in the accounting sector since the 2002 collapse of Arthur Andersen, the auditor that was mired in the Enron scandal and whose downfall reduced the Big Five to Big Four.

UK auditing and accounting regulator, the Financial Reporting Council, had asked the Big Four firms in 2020 to separate auditing as a standalone business in Britain by June 2024.

EY's latest move was first reported by the Financial Times.

Also Read: TCS Q4 Preview: Reliance on banking clients may keep earnings growth in check

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
Mar 20, 2024
11:00 AM EDT, 03/20/2024 (MT Newswires) -- New Fortress Energy ( NFE ) said Wednesday it has completed its acquisition of a 1.6-gigawatt capacity reserve electricity contract from a portfolio company of private equity firm Denham Capital. Under terms of the purchase agreement, New Fortress will issue a undisclosed amount of its series A convertible preferred stock to Denham Capital...
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Mar 20, 2024
11:01 AM EDT, 03/20/2024 (MT Newswires) -- Celularity ( CELU ) said Wednesday it submitted an application to the US Food and Drug Administration requesting an orphan drug designation for PDA-002 as a treatment for genetic muscle disorder facioscapulohumeral muscular dystrophy. The FDA has already approved the investigative new drug application for PDA-002 and Celularity ( CELU ) will start...
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
Mar 20, 2024
10:59 AM EDT, 03/20/2024 (MT Newswires) -- AAR (AIR) said Wednesday it has a multiyear agreement to provide surplus material for the CFM56-5B engine to Cebu Pacific. Financial details weren't disclosed. Under the accord, AAR said it will assist with the 30 scheduled shop visits for CFM56-5B engines that Cebu Pacific has scheduled throughout the contract period. Shares of ARR...
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Mar 20, 2024
10:57 AM EDT, 03/20/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Wednesday the US Food and Drug Administration has given orphan drug designation to CABA-201 to potentially treat systemic sclerosis. The candidate drug is being developed to treat autoimmune diseases driven by B cells, the company said, adding the clinical trial program has four phase 1/2 trials to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved